Using Light for Therapy of Glioblastoma Multiforme (GBM)

Glioblastoma multiforme (GBM) is the most malignant form of primary brain tumour with extremely poor prognosis. The current standard of care for newly diagnosed GBM includes maximal surgical resection followed by radiotherapy and adjuvant chemotherapy. The introduction of this protocol has improved...

Full description

Bibliographic Details
Main Authors: Alex Vasilev, Roba Sofi, Ruman Rahman, Stuart J. Smith, Anja G. Teschemacher, Sergey Kasparov
Format: Article
Language:English
Published: MDPI AG 2020-01-01
Series:Brain Sciences
Subjects:
Online Access:https://www.mdpi.com/2076-3425/10/2/75
id doaj-c162b3a7cd7c4305a92b93b5b7191ec8
record_format Article
spelling doaj-c162b3a7cd7c4305a92b93b5b7191ec82020-11-25T01:38:06ZengMDPI AGBrain Sciences2076-34252020-01-011027510.3390/brainsci10020075brainsci10020075Using Light for Therapy of Glioblastoma Multiforme (GBM)Alex Vasilev0Roba Sofi1Ruman Rahman2Stuart J. Smith3Anja G. Teschemacher4Sergey Kasparov5School of Physiology Pharmacology and Neuroscience, University of Bristol, Bristol BS8 1TD, UKSchool of Physiology Pharmacology and Neuroscience, University of Bristol, Bristol BS8 1TD, UKChildren’s Brain Tumour Research Centre, Nottingham Biodiscovery Institute, School of Medicine, University of Nottingham, Nottingham NG7 2RD, UKChildren’s Brain Tumour Research Centre, Nottingham Biodiscovery Institute, School of Medicine, University of Nottingham, Nottingham NG7 2RD, UKSchool of Physiology Pharmacology and Neuroscience, University of Bristol, Bristol BS8 1TD, UKSchool of Physiology Pharmacology and Neuroscience, University of Bristol, Bristol BS8 1TD, UKGlioblastoma multiforme (GBM) is the most malignant form of primary brain tumour with extremely poor prognosis. The current standard of care for newly diagnosed GBM includes maximal surgical resection followed by radiotherapy and adjuvant chemotherapy. The introduction of this protocol has improved overall survival, however recurrence is essentially inevitable. The key reason for that is that the surgical treatment fails to eradicate GBM cells completely, and adjacent parenchyma remains infiltrated by scattered GBM cells which become the source of recurrence. This stimulates interest to any supplementary methods which could help to destroy residual GBM cells and fight the infiltration. Photodynamic therapy (PDT) relies on photo-toxic effects induced by specific molecules (photosensitisers) upon absorption of photons from a light source. Such toxic effects are not specific to a particular molecular fingerprint of GBM, but rather depend on selective accumulation of the photosensitiser inside tumour cells or, perhaps their greater sensitivity to the effects, triggered by light. This gives hope that it might be possible to preferentially damage infiltrating GBM cells within the areas which cannot be surgically removed and further improve the chances of survival if an efficient photosensitiser and hardware for light delivery into the brain tissue are developed. So far, clinical trials with PDT were performed with one specific type of photosensitiser, protoporphyrin IX, which tends to accumulate in the cytoplasm of the GBM cells. In this review we discuss the idea that other types of molecules which build up in mitochondria could be explored as photosensitisers and used for PDT of these aggressive brain tumours.https://www.mdpi.com/2076-3425/10/2/75glioblastoma multiformephotodynamic therapyphotosensitiser
collection DOAJ
language English
format Article
sources DOAJ
author Alex Vasilev
Roba Sofi
Ruman Rahman
Stuart J. Smith
Anja G. Teschemacher
Sergey Kasparov
spellingShingle Alex Vasilev
Roba Sofi
Ruman Rahman
Stuart J. Smith
Anja G. Teschemacher
Sergey Kasparov
Using Light for Therapy of Glioblastoma Multiforme (GBM)
Brain Sciences
glioblastoma multiforme
photodynamic therapy
photosensitiser
author_facet Alex Vasilev
Roba Sofi
Ruman Rahman
Stuart J. Smith
Anja G. Teschemacher
Sergey Kasparov
author_sort Alex Vasilev
title Using Light for Therapy of Glioblastoma Multiforme (GBM)
title_short Using Light for Therapy of Glioblastoma Multiforme (GBM)
title_full Using Light for Therapy of Glioblastoma Multiforme (GBM)
title_fullStr Using Light for Therapy of Glioblastoma Multiforme (GBM)
title_full_unstemmed Using Light for Therapy of Glioblastoma Multiforme (GBM)
title_sort using light for therapy of glioblastoma multiforme (gbm)
publisher MDPI AG
series Brain Sciences
issn 2076-3425
publishDate 2020-01-01
description Glioblastoma multiforme (GBM) is the most malignant form of primary brain tumour with extremely poor prognosis. The current standard of care for newly diagnosed GBM includes maximal surgical resection followed by radiotherapy and adjuvant chemotherapy. The introduction of this protocol has improved overall survival, however recurrence is essentially inevitable. The key reason for that is that the surgical treatment fails to eradicate GBM cells completely, and adjacent parenchyma remains infiltrated by scattered GBM cells which become the source of recurrence. This stimulates interest to any supplementary methods which could help to destroy residual GBM cells and fight the infiltration. Photodynamic therapy (PDT) relies on photo-toxic effects induced by specific molecules (photosensitisers) upon absorption of photons from a light source. Such toxic effects are not specific to a particular molecular fingerprint of GBM, but rather depend on selective accumulation of the photosensitiser inside tumour cells or, perhaps their greater sensitivity to the effects, triggered by light. This gives hope that it might be possible to preferentially damage infiltrating GBM cells within the areas which cannot be surgically removed and further improve the chances of survival if an efficient photosensitiser and hardware for light delivery into the brain tissue are developed. So far, clinical trials with PDT were performed with one specific type of photosensitiser, protoporphyrin IX, which tends to accumulate in the cytoplasm of the GBM cells. In this review we discuss the idea that other types of molecules which build up in mitochondria could be explored as photosensitisers and used for PDT of these aggressive brain tumours.
topic glioblastoma multiforme
photodynamic therapy
photosensitiser
url https://www.mdpi.com/2076-3425/10/2/75
work_keys_str_mv AT alexvasilev usinglightfortherapyofglioblastomamultiformegbm
AT robasofi usinglightfortherapyofglioblastomamultiformegbm
AT rumanrahman usinglightfortherapyofglioblastomamultiformegbm
AT stuartjsmith usinglightfortherapyofglioblastomamultiformegbm
AT anjagteschemacher usinglightfortherapyofglioblastomamultiformegbm
AT sergeykasparov usinglightfortherapyofglioblastomamultiformegbm
_version_ 1725055091733430272